1. Skipper, H. E., Schabel, F. M., Ja., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother. Rep. 35, 1 (1964).
2. Schabel, F. M., Jr., Skipper, H. E., Trader, M. W., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XIX. Sensitivity of non-dividing leukemic cell populations to certain classes of drugs in vivo. Cancer Chemother. Rep. 48, 17 (1965).
3. Kline, I., Venditti, J. M., Tyrer, D. R., Goldin, A.: Chemotherapy of leukemia L 1210 in mice with 1-ß-D-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedule. Cancer Res. 26, 853 (1966).
4. Skipper, H. E., Schabel, F. M., Jr., Wilcox, W. S.: Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother. Rep. 51, 125 (1967).
5. Tyrer, D. D., Kline, I., Venditti, J. M., Goldin, A.: Separate and sequential chemotherapy of mouse leukemia L 1210 with 1-ß-D-arabinofuranosylcytosine hydrochloride and 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res. 27, 873 (1967).